Trials / Completed
CompletedNCT05707754
Sphenopalatine Ganglion Block Study
A Randomized Trial of a Sphenopalatine Ganglion Block With Bupivacaine for Acute Headache
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 220 (actual)
- Sponsor
- Montefiore Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The goal of this clinical trial is to compare the administration and dosage of bupivacaine for sphenopalatine ganglion (SPG) nerve block. The main question\[s\] it aims to answer are: * Does a high dose (3ml) give more relief than a low dose (1ml)? * Does bilateral administration give more relief than unilateral? Participants with headaches will be asked to lie down and have SPG block performed. Researchers will compare dosage and administration to see how symptoms are reduced.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bupivacaine | Topically applied to sphenopalatine ganglion |
| DEVICE | angiocatheter | Introduced into nose to reach sphenopalatine ganglion nerve |
Timeline
- Start date
- 2023-03-06
- Primary completion
- 2024-08-30
- Completion
- 2024-08-30
- First posted
- 2023-02-01
- Last updated
- 2024-10-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05707754. Inclusion in this directory is not an endorsement.